CommercialMay 1, 2023
Clinical Criteria updates for specialty pharmacy are available
Effective for dates of service on and after August 1, 2023, the following Clinical Criteria were developed and might result in services that were previously covered but may now be found to be not medically necessary.
CC-0096 | Asparagine Specific Enzymes |
CC-0128 | Tecentriq (atezolizumab) |
CC-0131 | Besponsa (inotuzumab ozogamicin) |
CC-0233 | Rebyota (fecal microbiota, live – jslm) |
Access the Clinical Criteria document information at https://anthem.com/ms/pharmacyinformation/clinicalcriteria.html
The Anthem Blue Cross and Blue Shield (Anthem) prior authorization clinical review of non-oncology specialty pharmacy drugs will be managed by Anthem’s medical specialty drug review team. Drugs used for the treatment of oncology will be managed by Carelon Medical Benefits Management, Inc. *
* Carelon Medical Benefits Management, Inc. is an independent company providing utilization management services on behalf of the health plan.
GABCBS-CM-022598-23
PUBLICATIONS: May 2023 Provider News
To view this article online:
Or scan this QR code with your phone